Monographie - Amphotericin B lipid complex

Última actualização :
19/11/2024

Amphotericin B lipid complex

estrutura química

Nomes comerciais nos diversos países

OS NOMES COMERCIAIS SÃO INDICATIVOS E OS EXCIPIENTES DA FORMULAÇÃO PODEM SER DIFERENTES CONFORME O PAÍS E FABRICANTE.

Abelcet

Alemanha, Argentina, Australia, Austria, Bélgica, Brasil, Canadá, Dinamarca, Espanha, Estados Unidos de América, Finlandia, França, Gran-bretanha, Grècia, Hungria, Irlanda, Itália, Luxemburgo, Malásia, México, Noruega, Países Baixos, Peru, Portugal, Romènia, Suècia

Bibliografía : Amphotericin B lipid complex

	tipo	publicação
1510	livro	AHFS Formulary service 2000 Bethesda - 3546 p
2247	jornal	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	jornal	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3254	jornal	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332	Laboratório	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3644	Laboratório	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3828	poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
4055	jornal	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44

Mentions Légales